PharmaMar will participate at the 17th European Large & MidCap Event to be held in Paris
October 03 2017 - 3:00AM
YASTEST
-
On October 4th and 5th,
PharmaMar will meet with European investors to increase awareness
of the Company and to explain in detail present and future
projects.
-
This 17th annual event will host 400
international investors with 140 listed companies
Madrid, 3rd, October,
2017. The biopharmaceutical Company PharmaMar (MSE:PHM)
will participate on the 4th and
5th of October,
in Paris, in the 17th European
Large & MidCap Event at which 400 international investors and
140 listed companies will participate.
For two days, PharmaMar will meet
with the most representative European investors in small and
midcaps through one on one meetings, sessions for questions and
answers as well as workshops, where present and future
projects in the field of oncology along with an update of its
latest corporate developments will be presented.
PharmaMar is a Company that has a
long history in the field of cancer investigation and which today
counts on a solid pipeline comprising of various molecules for
combating different solid and hematological tumors, such as
plitidepsina (Aplidin®), lurbinectedin (Zepsyre®), PM184 and PM14;
and a product on the market in over 75 countries worldwide,
Yondelis®, for soft tissue sarcoma and platinum-sensitive ovarian
cancer.
About
PharmaMar
Headquartered in Madrid, PharmaMar is a world-leading
biopharmaceutical company in the discovery and development of
innovative marine-derived anticancer drugs. The company has an
important pipeline of drug candidates and a robust R&D oncology
program. PharmaMar develops and commercializes YONDELIS®
in Europe and has three other clinical-stage programs under
development for several types of solid and hematological cancers,
Zepsyre(TM) (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a
global biopharmaceutical company with subsidiaries in Germany,
Italy, France, Switzerland, United Kingdom, Belgium, Austria and
the United States. PharmaMar fully owns other companies: GENOMICA,
Spain's leading molecular diagnostics company; Sylentis, dedicated
to researching therapeutic applications of gene silencing (RNAi);
and two other chemical enterprises, Zelnova Zeltia and Xylazel. To
learn more about PharmaMar, please visit us at
www.pharmamar.com.
Disclaimer
This document is a press release, not a prospectus. This document
does not constitute or form part of an offering or invitation to
sell or a solicitation to purchase, offer or subscribe shares of
the company. Moreover, no reliance should be placed upon this
document for any investment decision or contract and it does not
constitute a recommendation of any type with regard to the shares
of the company.
Media Contact:
Alfonso Ortín - Communications Director aortin@pharmamar.com
Mobile: + 34609493127
Paula Fernández - Media Relations Manager pfalarcon@pharmamar.com
Mobile: +34 638796215
Phone: +34 918466000
Investor Relations:
José Luis Moreno - Investor Relations & Capital Markets
Director. investorrelation@pharmamar.com
Phone: +34 914444500
Or please visit our website at www.pharmamar.com
Press release (PDF)
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Pharma Mar, S.A via Globenewswire
PulteGroup (NYSE:PHM)
Historical Stock Chart
From Mar 2024 to Apr 2024
PulteGroup (NYSE:PHM)
Historical Stock Chart
From Apr 2023 to Apr 2024
